Amylyx Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 4/4
Amylyx Pharmaceuticals VD är Josh Cohen, utsedd i Jan 2013, har en mandatperiod på 13.33 år. totala årliga ersättningen är $ 2.72M, bestående av 25.2% lön 74.8% bonusar, inklusive företagsaktier och optioner. äger direkt 2.8% av företagets aktier, värda $ 42.25M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.3 år respektive 5.3 år.
Viktig information
Josh Cohen
Verkställande direktör
US$2.7m
Total ersättning
| VD-lön i procent | 25.23% |
| Anställning som VD | 13.3yrs |
| Ägande av VD | 2.8% |
| Ledningens genomsnittliga anställningstid | 5.3yrs |
| Styrelsens genomsnittliga mandatperiod | 5.3yrs |
Senaste uppdateringar av ledningen
Recent updates
Ny berättelse • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 27
Amylyx Pharmaceuticals: Back From The Dead
Summary Amylyx Pharmaceuticals has rebounded sharply since its nadir in 2024, driven by the acquisition of avexitide and renewed pipeline optimism. Avexitide targets post-bariatric hypoglycemia, an underserved market with no approved therapies and significant unmet need. Street sentiment is bullish on AMLX, but current valuation appears fair given projected sales and patient penetration. An analysis around Amylyx Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...Analysartikel • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...
Ny berättelse • Apr 01
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking AlphaAnalysartikel • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...Analysartikel • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking AlphaAnalysartikel • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...Analysartikel • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking AlphaAnalysartikel • Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Unfortunately for some shareholders, the Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has dived 31% in the...Analysartikel • Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Today is shaping up negative for Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders, with the analysts...Seeking Alpha • Mar 09
An ALS Drug Fails Again
Summary The ALS drug (Relyvrio) had been put through a Phase II trial by its developer, Amylyx. Amylyx was already working on a Phase III trial, and they committed to withdrawing the drug if this trial showed no efficacy. Just like with the recent approvals in Alzheimer's, the patient advocacy groups took victory laps after Relyvrio was approved, and they were a big part of the pressure that made the FDA reverse its initial correct decision. Read the full article on Seeking AlphaSeeking Alpha • Feb 23
Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Summary Amylyx Pharmaceuticals' stock has rebounded by 50% since a rating downgrade in November, reflecting investor relief after Q4 earnings were in line with expectations. The company provided an earlier timeline for Phase 3 PHOENIX trial data, which will impact the market prospects of its ALS drug, Relyvrio. Positive PHOENIX trial data could boost Amylyx's stock by 200%, while negative data could send it down by at least 50%. Read the full article on Seeking AlphaAnalysartikel • Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have been powering on, with a gain...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$150m |
| Dec 31 2025 | US$3m | US$686k | -US$145m |
| Sep 30 2025 | n/a | n/a | -US$149m |
| Jun 30 2025 | n/a | n/a | -US$188m |
| Mar 31 2025 | n/a | n/a | -US$219m |
| Dec 31 2024 | US$6m | US$686k | -US$302m |
| Sep 30 2024 | n/a | n/a | -US$259m |
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Ersättning vs marknad: Josh s total kompensation ($USD 2.72M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 5.47M ).
Ersättning vs inkomst: Ersättningen från Josh har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Josh Cohen (33 yo)
13.3yrs
Anställning
US$2,719,807
Kompensation
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 13.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Co-CEO & Director | 13.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Chief Financial Officer | 5.3yrs | US$1.38m | 0.19% $ 2.9m | |
| Chief Medical Officer | 2.5yrs | US$1.57m | 0.080% $ 1.2m | |
| Chief Technical Operations Officer | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations & Communications | no data | inga uppgifter | inga uppgifter | |
| Chief Legal Officer & General Counsel | 4.3yrs | US$2.30m | 0.053% $ 801.8k | |
| Chief Human Resources Officer | 2.3yrs | inga uppgifter | inga uppgifter | |
| Global Head of Regulatory Affairs | 5.8yrs | inga uppgifter | inga uppgifter | |
| VP & Head of Global Medical Affairs | 6yrs | inga uppgifter | inga uppgifter | |
| Head of Global Medical Strategy & Communications | no data | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | 1.3yrs | inga uppgifter | inga uppgifter |
5.3yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder
Erfaren ledning: AMLX s ledningsgrupp är erfaren och erfaren ( 5.3 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Co-CEO & Director | 12.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Special Advisor & Member of Advisory Board | 5.3yrs | US$51.24k | inga uppgifter | |
| Independent Chairman of the Board | 11.3yrs | US$218.58k | 0.73% $ 11.0m | |
| Chairman of The Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 3.2yrs | US$161.08k | 0.057% $ 856.9k | |
| Independent Director | 4.9yrs | US$173.58k | 0.0045% $ 67.9k | |
| Independent Director | 2.2yrs | US$166.08k | 0.0090% $ 135.7k | |
| Independent Director | 5.2yrs | US$168.58k | 0.0036% $ 53.6k |
5.3yrs
Genomsnittlig anställningstid
64yo
Genomsnittlig ålder
Erfaren styrelse: AMLX s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 09:02 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Amylyx Pharmaceuticals, Inc. bevakas av 13 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |